perifosine has been researched along with Epithelial Ovarian Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbasi, F; Al Sawah, E; Apte, SM; Bou Zgheib, N; Chen, X; Chon, HS; Judson, PL; Lancaster, JM; Marchion, DC; Ramirez, IJ; Wenham, RM; Xiong, Y | 1 |
| Atkinson, E; Bast, RC; Coleman, RL; Coombes, KR; Dice, K; Dyer, M; Fu, S; Gershenson, DM; Hennessy, BT; Howard, A; Jackson, E; Ju, Z; Kavanagh, JJ; Kundra, V; Kurzrock, R; Levenback, CF; Li, J; Li, Y; Markman, M; Mills, GB; Ng, CS; Sood, AK; Stemke-Hale, K; Wolf, JK | 1 |
1 trial(s) available for perifosine and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Grading; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Phosphorylcholine; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Taxoids | 2012 |
1 other study(ies) available for perifosine and Epithelial Ovarian Cancer
| Article | Year |
|---|---|
Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Cisplatin; Humans; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RNA; Signal Transduction | 2013 |